NRXP Stock Forecast: NRX Pharmaceuticals, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for NRX Pharmaceuticals, Inc. is $47. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 19 of 100 as at 18 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores NRX Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (73): Sales and profits are climbing, and climbing faster than before.
Value (8): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
NRXP stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NRXP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Nov 2026 | BTIG | Maintains | Buy | $10 → $12 |
| 2 Nov 2026 | Ascendiant Capital | Maintains | Buy | $50 → $51 |
| 1 Oct 2026 | Ascendiant Capital | Maintains | Buy | $49 → $50 |
| 14 Sept 2026 | BTIG | Reiterates | Buy | $10 |
| 25 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $45 |
| 18 Aug 2026 | BTIG | Reiterates | Buy | $10 |
| 7 Aug 2026 | BTIG | Maintains | Buy | $25 → $10 |
| 5 May 2026 | D. Boral Capital | Maintains | Buy | $34 |
| 27 Apr 2026 | Ascendiant Capital | Maintains | Buy | — |
| 27 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 23 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 20 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 24 Mar 2026 | BTIG | Reiterates | Buy | — |
| 24 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 17 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 16 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 9 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 3 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Feb 2026 | BTIG | Reiterates | Buy | — |
| 17 Feb 2026 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NRXP.
This page is one stock. Monday covers all of them.
NRXP appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
NRXP vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 19 Nov 2026, NRX Pharmaceuticals, Inc. returned +19.7% against +9.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
NRXP analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 28.8×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 6% of US stocks
- Revenue growth (YoY)
- 378.9%
- Earnings growth (YoY)
- —
- Gross margin
- 38.7%
- Operating margin
- —
- Net margin
- —
Higher than 97% of US stocks
Higher than 47% of US stocks
- Return on equity
- —
- Return on assets
- −70.1%
- Dividend yield
- —
Higher than 5% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
NRX Pharmaceuticals, Inc. has a market value of $122.2M and an enterprise value of $105.3M.
Revenue in the twelve months to 30 June 2026: $3.4M.
Net income over the same four quarters: −$23.5M, a −691.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$20.7M.
NRX Pharmaceuticals, Inc. employs 29 people — $117K of revenue per employee.
Data provided by Twelve Data
NRXP and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at NRXP’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own NRX Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about NRXP
What is the NRXP stock price forecast for 2026-2027?
The median 12-month analyst price target for NRX Pharmaceuticals, Inc. is $47, with estimates ranging from $12 to $51. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is NRXP stock a buy right now?
Of the 4 analysts covering NRX Pharmaceuticals, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NRX Pharmaceuticals, Inc. 19 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank NRXP?
As at 18 Nov 2026, NRX Pharmaceuticals, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (73 of 100).
Will NRXP stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts is $47, and Ticker Nerd's factor model ranks NRX Pharmaceuticals, Inc. 19 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the NRXP stock forecast for 2030?
No analyst covering NRX Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NRXP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $51 over the next 12 months.
How has NRXP stock performed over the past year?
NRX Pharmaceuticals, Inc. returned +19.7% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does NRX Pharmaceuticals, Inc. do?
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, with an emphasis on severe depression, bipolar depression, post-traumatic stress disorder, and related suicidal ideation. Its current pipeline centers on NRX-100, a preservative-free intravenous ketamine formulation, and NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone.
About NRX Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, with an emphasis on severe depression, bipolar depression, post-traumatic stress disorder, and related suicidal ideation. Its current pipeline centers on NRX-100, a preservative-free intravenous ketamine formulation, and NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone. The company also works on adjacent neuropsychiatric and respiratory care initiatives through its broader portfolio and operating segments. NRx Pharmaceuticals, Inc. serves a specialized role in psychiatry by targeting high-unmet-need conditions where conventional treatment options may be limited or insufficient. Headquartered in Wilmington, Delaware, it operates as a focused developer of novel therapeutics for complex mental health and neurological indications.
CEO Dr. Jonathan C. Javitt M.D., M.P.H. · 29 employees · United States · https://www.nrxpharma.com